<DOC>
	<DOCNO>NCT02302716</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy study drug know LY2963016 compare LANTUS® adult type 2 diabetes mellitus 2 oral antihyperglycemic medication ( OAMs ) .</brief_summary>
	<brief_title>A Study LY2963016 Compared LANTUS® Adult Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Have type 2 diabetes mellitus ( T2DM ) . Have receive 2 OAMs stable dos 12 week prior screen , without basal insulin . If currently basal insulin , must take LANTUS® QD NPH insulin detemir either QD twice day least 90 day prior study entry . Have HbA1c ≥7.0 % ≤11.0 % insulin naïve ; previously basal insulin , HbA1c ≤11.0 % . Body mass index ( BMI ) ≤45 kilogram per meter square ( kg/m^2 ) . As determined investigator , capable willing following : perform self monitor blood glucose ( SMBG ) complete participant diary instruct receptive diabetes education comply require study treatment study visit Have LANTUS® daily within previous 30 day . Have use insulin except entry insulin [ LANTUS® , insulin detemir , NPH ] include commercial ( include premixed insulin ) investigational insulin within previous 30 day . Have expose biosimilar insulin glargine within previous 90 day . Have participate LY2963016 study . Have take basal plus mealtime insulin ( basal bolus therapy ) within last year great 4 continuous week . Have use glucagon like peptide ( GLP1 ) receptor agonist within previous 90 day . Have use pramlintide within previous 30 day . Have excessive insulin resistance study entry ( total insulin dose ≥1.5 units/kg ) . Have 1 episode severe hypoglycemia within 6 month prior screen . Have 2 emergency room visit hospitalization due poor glucose control 6 month prior screen . Have know hypersensitivity allergy LANTUS® excipients . Are receive chronic ( lasting longer 14 consecutive day ) systemic glucocorticoid therapy receive therapy within 4 week immediately precede screen . Have obvious sign symptom , laboratory evidence , liver disease . Have one follow concomitant disease : significant cardiac ( e.g. , congestive heart failure Class III IV ) gastrointestinal disease ( e.g. , significant gastroparesis ) . Have history renal transplantation currently receive renal dialysis . Have serum creatinine great 2.0 milligrams/deciliter ( 177 micromoles/liter ) . Have blood transfusion severe blood loss within 3 month prior screen know hemoglobinopathy , hemolytic anemia , sickle cell anemia . Participants active cancer personal history cancer within previous 5 year ( exception basal cell carcinoma carcinoma situ ) . Have history diagnosis Human Immunodeficiency Virus ( HIV ) infection . Have condition ( include know drug alcohol abuse psychiatric disorder include dementia ) preclude participant follow complete protocol . Are pregnant intend become pregnant course study . Women breastfeed . Are currently enrol , discontinue within last 30 day , clinical trial involve investigational product nonapproved use drug device LY2963016 , concurrently enrol type medical research judge scientifically medically compatible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>